OneMedNet Corporation (ONMD) saw its stock price rise to $1.10 on Friday, buoyed by insider filings that revealed roughly $1.5 million in new commitments from executives and directors. The clinical data company, which is working to convert its Palantir-supported platform into steady sales, traded on volume exceeding 11.6 million shares, according to market data.
The rebound comes after Nasdaq warned the company on April 14 that its common shares had closed below the $1 minimum bid for 30 consecutive business days. OneMedNet now faces an October 12 deadline to regain compliance: shares must trade at $1 or higher for at least 10 consecutive business days.
Insider Purchases Signal Confidence
Chief Medical Officer Jeffrey Yu acquired 903,614 shares at $0.83 each in an April 1 subscription deal, investing $750,000. He also received 219,429 shares in lieu of cash previously owed, bringing his direct holdings to 8,449,266 shares. Director Thomas Kosasa, who owns 10% of the company, disclosed purchases of 595,238 shares at $0.84 on February 6 and an additional 280,898 shares at $0.89 on April 23, totaling $750,000. After these moves, Kosasa’s holdings reached 16,661,327 shares.
Palantir-Powered Platform Goes Live
Just two days before the stock surge, OneMedNet announced its iRWD platform—powered by Palantir Foundry—was live, offering searchable access to 80 million patient journeys and billions of records. The platform focuses on imaging real-world data (RWD), which captures health information outside clinical trial settings, including de-identified clinical images and associated records. CEO Aaron Green stated that subscription users can now “find the data they need in seconds.”
The company also reported its network has grown by roughly 70%, now covering 80 million patients and 251 million studies. Access is available for approximately 47 million tokenized patients via Datavant, using coded IDs to connect records while maintaining patient confidentiality.
Financial Crunch and Competitive Landscape
OneMedNet is entering a crowded real-world data market dominated by larger players. IQVIA claims access to over 1.2 billion non-identified patient records, TriNetX’s LIVE network covers more than 300 million de-identified patients, and Komodo Health’s Healthcare Map tracks over 330 million patient journeys. OneMedNet operates on a smaller scale, with total revenue of $1.4 million in 2025—a 111% increase from 2024—driven by a $1.0 million boost in iRWD data-delivery revenue. The company shut down its legacy BEAM platform in May 2025.
Despite revenue growth, OneMedNet faces significant financial challenges. The company reported net losses of $2.8 million in 2025 and $10.1 million in 2024, with an accumulated deficit of $104.4 million. Year-end cash stood at just $0.6 million. In its annual filing, OneMedNet expressed “substantial doubt” about its ability to continue as a going concern, noting it may need additional funding.
The company is targeting subscription revenue growth and expects to win more customers in the second and third quarters. However, its own filings acknowledge that competitors may outgun it on resources, and that competing technologies could pressure sales, pricing, and margins.
